Company Overview

Cytonics is a biotechnology research and development company that specializes in developing diagnostics and therapeutics for osteoarthritis. Our flagship product was the Fibronectin-Aggrecan Complex Test (“FACT™”), which can detect cartilage damage due to osteoarthritis from samples of patients’ joint fluid. We licensed FACT™ to Synthes (acquired by Johnson & Johnson) in 2011, and it has been used by hundreds of physicians to diagnose and direct patients’ course of treatment.

Discovery of FAC as a biomarker for osteoarthritis led to the identification of a naturally-occurring blood protein, Alpha-2 Macroglobulin (A2M), which protects cartilage from degradation and can alleviate joint pain. We developed an autologous therapy (“APIC™”) based upon the function of A2M, which has sold directly to physicians by a national medical device distributor since 2015. Over 6,000 patients, ranging from the elderly to young athletes, have been treated to date. We are developing new A2M-based therapies with the goal of out-licensing to strategic partners at critical clinical value inflection points. Cytonics’ mission is to rid the world of the pain, suffering, and reduced quality of life caused by osteoarthritis. Supported by hundreds of physicians nationwide, we are a leader in the field of regenerative medicine and are positioned to disrupt the space with our innovative biologic therapies for osteoarthritis.

Our mission is to rid the world of the pain, suffering, and reduced quality of life caused by osteoarthritis.

Our Research

APIC™ SYSTEM
APIC™ SYSTEMOur breakthrough technology is based upon a naturally occurring molecule within the body. This molecule, alpha-2-macroglobulin (A2M), is found within...Learn More
CYT-108
CYT-108We have designed and tested a synthetic (recombinant) version of the naturally occuring A2M molecule. This recombinant therapy improves upon Nature's design and...Learn More
FACT™ Diagnostic
FACT™ DiagnosticWe have developed biomarker assay (Fibronective-Aggrecan Complex Test, FACT™) to identify symptomatic intervertebral discs or painful joint abnormalities. FACT™ is used to...Learn More
Intellectual Property
Intellectual PropertyCytonics has made considerable investments in R&D and has filed numerous domestic and international patent applications for its diagnostic and therapeutic technologies...Learn More

Testimonials

Alexander-Vaccaro
“I was an early investor in Cytonics as the technology is timely in unraveling the etiology of Low back pain. The future will be assaying for specific biomarkers to determine not only the cause of pain but the potential for improvement with certain interventions. As a busy spine surgeon for the last 25 years the direction that Cytonics is proceeding in attempting to minimize clinical failures through their Autologous Platelet Integrated Concentration (APIC) System is breathtaking and timely.”
Alexander-Vaccaro
Alexander R Vaccaro, MD, PhD, MBA
L_rosenfield
"I have been using Cytonics’ alpha2- macroglobulin kits to treat various joint pains mostly in the knee. This is part of my regenerative medicine practice. I’ve seen remarkable results such that I have suggested that my wife and my son undergo treatments as well as patients. The treatments were remarkably successful in both of them. I am very pleased and I’m looking forward to having this product available more easily off-the-shelf and approved by insurance. I expect a huge demand for it. Thank you."
L_rosenfield
Laurence Rosenfield, MD
martinAngst
“Cytonics’ recombinant drug development program is anchored in robust preclinical data indicating that the proteinase inhibitor alpha-2-macroglobulin critically inhibits cartilage breakdown in models of osteoarthritis. Cytonics has developed a lead recombinant drug candidate, a variant of human alpha-2-macroglobulin that possesses a unique and improved bioactivity profile. Cytonics’ strategic efforts are exciting as they target the development of a first biologic therapy for patients suffering from osteoarthritis.”
martinAngst
Martin Angst, MD
GailCrop
“[Dr. Scuderi] took out some of my blood and he put it into the centrifuge and they did what they had to do and then he reinjected the A2M protein back into my knee. Before he did the procedure, I could not bend my knee, I could not walk upstairs. I really couldn't do anything. In fact, I was using a brace on my knee just to give me some support because the whole knee felt like it was going to cave in. A few days after the procedure I was walking and we were walking the dogs and the swelling seemed to have been going down.”
GailCrop
Gail Lynn
BobCrop
“I came with Gail when she discovered Dr. Scuderi and what he can do for arthritis. I went for an x-ray. Very simply, he did the same procedure. He took blood from my arm and put it in a centrifuge and got the protein out and injected it in my shoulder. And I’ve been great. We had nothing but success with this protein shot.”
BobCrop
Robert Lynn
image016
“I partially tore my ACL in a skiing accident in Switzerland.  After an unnecessary arthroscopy revealed I was not a candidate for ACL reconstruction, my knee was swollen and stiff for 6 weeks.  Then I had a single treatment of Cytonics A2M therapy, APIC.  Within 2 days the swelling and stiffness was gone and hasn’t returned 6 months later.  I was so impressed with these results that I have been evangelizing for APIC treatment to my doctors and friends ever since. Even if I need another treatment soon, a couple APIC injections per year with no noticeable side effects and no drugs is closer to a miracle-treatment than I imagined possible before my experience with Cytonics’ product.  Joint injuries can be physically and emotionally debilitating, but medical advancements like this make now the best time in history to tear one’s ACL."
image016
Gabe
DaryleBobb
“I suffered prolonged pain from a partial tear in my right Achilles tendon.  I am very familiar with this pain as I ruptured and had my left Achilles surgically repaired.  After almost eight months of therapy and various treatments, Richard Grossman, MD told me about Cytonics and the available A2M treatment.  I received my first injection in April of 2018 and within weeks the large nodule in my Achilles had shrunk significantly.  While I was feeling much better and able to start playing basketball and tennis again for the first time in ten months, I still felt a little pain.  I went back for a 2nd injection in November of 2018 and the pain has been reduced to only minor pain with NO LIMITATIONS.  The A2M therapy has given me my sports and mobility life back and I have recommended this treatment to all of my friends.”
DaryleBobb
Daryle Bobb
Pasquale-X-Montesano-3
As a practicing spine surgery specialist for over 33 years, I have never experienced a treatment as effective as Cytonics’ APIC therapy! I currently perform a minimum of 3 APIC injections per week and have treated world champion Jiu Jitsu competitors (I’m a practitioner of the great martial art myself!) and US Army Special Forces soldiers with outstanding success. I ask my patients repeatedly “how did the APIC treatment go, do you have any lingering pain?” I have received an almost unanimous response of “all of the pain has subsided.” I honestly cannot believe the results. Cytonics is the only company producing an A2M product that I would treat my patients with. I have so much confidence in Cytonics’ APIC treatment that I am scheduling myself to receive an injection in my wrist!
Pasquale-X-Montesano-3
Pasquale Montesano, MD

“The individuals above were not compensated in exchange for their testimonials. In addition, their testimonials should not be construed as and/or considered investment advice.”

Our Partnerships

The company has developed relationships with researchers and clinicians at leading institutions around the country including Stanford University, University of Pittsburgh, Thomas Jefferson University, University of Michigan, NYU Hospital For Joint Diseases, and Beaumont Health System. Cytonics also has relationships with local institutions including The Scripps Research Institute, Florida Atlantic University, and Palm Beach State College.  The company has sponsored research at Stanford University to study the use of FACT™ for patients with radiculopathic back pain, and at the University of Pittsburgh to investigate the effect of APIC™ on preventing spinal disc degeneration.